Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...

While the best companies are hard to find, but they can generate massive returns over long periods. To wit, the BioNTech SE ...

Morgan Stanley analyst Terence Flynn maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of ...

One of the cornerstones of being prepared for the next pandemic is being in the best position possible to design and deploy a ...

Provides updates on BioNTech’s strategy to scale and deploy AI-capabilities across the immunotherapy pipeline Highlights InstaDeep’s new near exascale supercomputer, Kyber, with the aim of ...

Company Conference Call October 1, 2024 9:00 AM ETCompany ParticipantsKarim Beguir - Chief Executive Officer, InstaDeepUğur ...

This AI aims to facilitate interdisciplinary collaboration and uncover unexpected connections in scientific research.

In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Buy rating on BioNTech SE (BNTX – Research Report), with ...

Thomas Kwan, initially pleaded not guilty to attempted murder but reversed his plea after prosecutors presented their evidence.

The BioNTech SE ADR BNTX advanced 2.40% to $122.68 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.90% to 5,751.07 and the ...

BioNTech has a broad and diversified cancer drug pipeline extending well beyond mRNA based approaches. Sam Fazeli, Senior Health Care Analyst, speaks to Ryan Richardson, Chief Strategy Officer, who ...